The University of Western Ontario
- Country
- 🇨🇦Canada
- Ownership
- Private
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
13
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Exploring a Natural Solution for Childhood Obesity
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Western University
- Target Recruit Count
- 30
- Registration Number
- NCT07033767
WECARE APD: Assessing a Single Multidisciplinary Team Visit for Atypical Parkinsonian Disorders
- Conditions
- Parkinson Plus
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Western University
- Target Recruit Count
- 30
- Registration Number
- NCT06836921
Passive Thoughts in Functional Movement Disorders
- Conditions
- Functional Movement Disorder
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Western University, Canada
- Target Recruit Count
- 60
- Registration Number
- NCT06439017
- Locations
- 🇨🇦
Aditya Murgai, London, Ontario, Canada
Handwriting Analysis in Movement Disorders.
- Conditions
- Movement Disorders
- First Posted Date
- 2024-05-31
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Western University, Canada
- Target Recruit Count
- 100
- Registration Number
- NCT06436287
- Locations
- 🇨🇦
Aditya Murgai, London, Ontario, Canada
[18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma
- Conditions
- Metastatic Clear Cell Renal Cell Carcinoma
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Western University
- Target Recruit Count
- 30
- Registration Number
- NCT06428708
- Locations
- 🇨🇦
London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada
- Prev
- 1
- 2
- Next
News
LivaNova's CORE-VNS Study Demonstrates Sustained Seizure Reduction in Drug-Resistant Epilepsy Patients
LivaNova's comprehensive CORE-VNS study of over 800 patients worldwide demonstrates sustained effectiveness of VNS Therapy for drug-resistant epilepsy over 36 months.
Global Clinical Trial Launches to Test Sipavibart as Potential Long COVID Treatment
Nova Southeastern University researchers have begun a clinical trial testing AstraZeneca's monoclonal antibody sipavibart as a potential treatment for Long COVID, funded by the Schmidt Initiative for Long COVID.
ORATOR Trial: Radiotherapy and Transoral Robotic Surgery Show Similar Outcomes in Oropharyngeal Cancer
The phase II ORATOR trial compared radiotherapy and transoral robotic surgery for oropharyngeal squamous cell carcinoma, revealing similar oncologic outcomes at 5 years.